The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / The End of the Beginning: COVID-19 Vaccines & Other Conundrums

The End of the Beginning: COVID-19 Vaccines & Other Conundrums

December 9, 2020 • By Philip Seo, MD, MHS

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In phase 1b, essential workers will take priority. This includes teachers, emergency responders, corrections officers and those who work in the food industry, agriculture, utilities and transportation, none of whom can avoid contact with other people. In phase 1c, priority will go to adults who are older than 65 years or have comorbid conditions that place them at risk for poor outcomes from COVD-19. Together, these phases represent another 250 million Americans. Again to put this in perspective, the U.S. government has currently purchased enough vaccine from Pfizer and Moderna to vaccinate 100 million Americans.12 Total.

You Might Also Like
  • ACR Convergence 2020: Progress Toward COVID-19 Vaccines
  • COVID-19 Immunization Day: It Won’t Be Long Before We Can Hug Again
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
Also By This Author
  • Thinking Big, Thinking Small

What makes these decisions even more weighty is the implied ethical decisions. If we wish to limit mortality, the elderly should be vaccinated first. If we wish to limit disease spread, then vaccinating essential workers makes more sense. But people who work in childcare, elder care and public transportation have even higher rates of developing COVID-19 than other essential workers; shouldn’t they hop to the front the list?13 On the other hand, vaccinating teachers first may allow us to open schools earlier than would have been possible otherwise. The incarcerated pose a particularly sticky issue: It is impossible to socially distance in prison. Where should they fall in line?

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

There are also many unknowns: How effective will these vaccines be in immunocompromised or immunosuppressed patients? More specifically, will the RNA-based vaccines cause lupus patients to flare by inducing a type I interferon response? And how good are these vaccines at preventing the asymptomatic infections that are responsible for much of the pandemic? The AstraZeneca vaccine reduces SARS-CoV-2 RNA-positivity among asymptomatic patients, but what about the Moderna and Pfizer vaccines? We just don’t know.14

Of course, none of this may matter if no one agrees to get vaccinated.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In November, the Pew Research Center conducted a survey of 12,648 Americans and found that 60% would be willing to be vaccinated against SARS-CoV-2.15 In most ways, that’s good news. First, we assume that interest in the vaccine will climb as friends and neighbors continue to be hospitalized with COVID-19 in ever escalating numbers. Second, an additional 21% of those surveyed would probably be willing to receive the vaccine; they just want more information. And they want to see others go first. That brings us to 81%, which is around what we would need to achieve herd immunity; if four out of every five Americans agree to be vaccinated, we may be able to hamper the spread of SARS-CoV-2 just enough to tame the pandemic.

Pages: 1 2 3 4 5 6 | Single Page

Filed Under: Rheuminations Tagged With: COVID-19

You Might Also Like:
  • ACR Convergence 2020: Progress Toward COVID-19 Vaccines
  • COVID-19 Immunization Day: It Won’t Be Long Before We Can Hug Again
  • ACR/ARHP Annual Meeting 2012: Immunosuppressed Rheumatic Disease Patients Still Candidates for Vaccines
  • Early Lessons from the COVID-19 Pandemic: A Q&A with Chris Phillips, MD

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.